<div>
  <p>
  </p>
  <ul>
    <li>
      <p>
        Genetic testing and CDx tools provider Personalis entered a partnership with genetic testing and bioinformatics company Tempus Labs to collaboratively commercialize Personalis' NeXT Personal Dx Minimal Residual Disease (MRD) assay, which enables personalized ctDNA panels of up to 1,800 variants with a resolution of around one part per million. The companies intend to initially focus on MRD testing in lung cancer.
      </p>
    </li>
    <li>
      <p>
        Under the partnership, Tempus is expected to integrate the tumor-informed, whole-genome liquid biopsy assay into its testing menu, market it to oncologists, and pay Personalis up to USD 12 million as milestone payments to fund the clinical testing.
      </p>
    </li>
    <li>
      <p>
        Personalis, on the other hand, would pay Tempus for the fair market value of sales, marketing, order requisition, and results delivery services and provide Tempus with warrants to buy up to ~9.2 million shares of Personalis' common stock over the next two years. Personalis would also receive, process, and bill any tests, manage reimbursement, and perform clinical validation tasks in breast cancer and immunotherapy monitoring.
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.genomeweb.com/business-news/personalis-tempus-partner-commercialize-blood-based-minimal-residual-disease-test">
      Genome Web
    </a>
  </p>
  <p>
  </p>
</div>


Precision Medicine

PROMINENT_CATEGORY

<div>
 
 <p>Genetic testing and CDx tools provider Personalis has partnered with genetic testing and bioinformatics company Tempus Labs to commercialize Personalis' NeXT Personal Dx Minimal Residual Disease (MRD) assay. The assay allows for personalized ctDNA panels with high resolution. Initially, the focus will be on MRD testing in lung cancer.</p>
 <p>Under the partnership, Tempus will integrate the liquid biopsy assay into its testing menu, market it to oncologists, and pay Personalis milestone payments of up to USD 12 million for clinical testing. Personalis will compensate Tempus for sales, marketing, order requisition, and results delivery services. They will also provide warrants to buy shares and handle breast cancer and immunotherapy monitoring.</p>
 
</div>

Personalis collaborates with Tempus Labs to commercialize NeXT Personal Dx minimal residual disease assay

DISRUPTOR_PRESENT

INCUMBENTS_PRESENT

<div>
 <ul>
  <li><p>Genetic testing and bioinformatics company Tempus has partnered with pharmaceutical company Bristol Myers Squibb for strategic cancer research. The collaboration aims to identify and validate new drug targets using multimodal datasets, computational approaches, and disease models derived from patients.</p></li>
  <li><p>The research will focus on finding options for patients who have no effective therapies or are unresponsive to current treatments. The teams will analyze disease cohorts and utilize Tempus' multimodal database and patient-derived organoids for iterative testing of potential targets.</p></li>
 </ul>
</div>

All Updates

Personalis collaborates with Tempus Labs to commercialize NeXT Personal Dx minimal residual disease assay

Tempus collaborates with Bristol Myers Squibb for cancer research using AI

Tempus and CureMD collaborate on integrating genomic-testing functionality in EHR

Tempus receives FDA Breakthrough Device Designation for companion diagnostic test

Tempus and AstraZeneca collaborate on NSCLC trial for biomarker discovery

Tempus and TScan Therapeutics partner to develop companion diagnostic test

Tempus launches AI-enabled clinical assistant, Tempus One

Tempus receives FDA premarket approval for its companion diagnostic test

Tempus partners with Pfizer to advance oncology therapeutic development

Tempus partners with Actuate Therapeutics to discover biomarker profiles for Elraglusib